Orrick Advises Intersect Power on Securing US$750 Million Growth Investment
| June.29.2022

| June.29.2022
| June.27.2022
The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor.
| June.22.2022
| June.10.2022
| June.06.2022
Returning investor OMERS Growth Equity led the round, which also included Fidelity Management & Research Company and other current investors.
| June.06.2022